August 6, 2024 C-Path Welcomes New Advisory Members to Alpha-1 Antitrypsin Deficiency Consortium C-Path's Critical Path for Alpha-1 Antitrypsin Deficiency (CPA-1) consortium today announced the addition of several...
July 31, 2024 Meet the Team — Q&A with Clinical Outcome Assessment Scientist Cole Ayasse I am a Clinical Outcome Assessment (COA) Scientist in the COA Program at C-Path.
July 26, 2024 C-Path’s Alzheimer’s Consortium Unveils Seminal Methodology to Enhance Alzheimer’s Clinical Trials Using Imaging Biomarkers C-Path is proud to announce the publication of a new study in the journal Alzheimer’s & Dementia...
June 24, 2024-June 25, 2024 C-Path’s Stephenson to Serve as Co-panelist for FNIH Digital Technologies Summit C-Path's Executive Director, Critical Path for Parkinson's (CPP) Consortium, Diane Stephenson will join as a...
June 20, 2024 C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development C-Path, a leader in forming collaborations that accelerate drug development, and Centogene N.V. (Nasdaq: CNTG)...
June 20, 2024 C-Path Partners with FARA to Fortify RDCA-DAP and Further Accelerate Drug Development with new Friedreich’s Ataxia Data C-Path announced the targeted integration of additional Friedreich’s ataxia...
June 12, 2024 C-Path’s Parkinson’s Consortium Supports Groundbreaking Research Utilizing Smartwatches to Monitor Disease Progression Critical Path Institute (C-Path) today announced a new publication on how the use of wearable technology...
June 10, 2024 Advocate Sarah Dolan Brings a Patient Voice to FDA Committee Reviewing New Alzheimer’s Drug Donanemab On Monday, June 10, the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Drugs Advisory...
May 30, 2024 C-Path Supports Gleason, ALS Community at IgNight ALS The C-Path team was incredibly humbled to be a part of IgNight ALS recently in Washington, D.C., honoring Steve Gleason and celebr
May 23, 2024 C-Path’s RDCA-DAP Webinar, “The Use and Development of DHTs with Patient Advocacy Groups” a Hit, with Keynote, Patient Advocacy Panel, and Engaged QAs Critical Path Institute’s Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®), part of C-Path's Rare...